Clene Q1 net loss $11.1M ($0.09/shr); cash $27.9M; VISIONARY-MS data positive

Clene Inc.

Cash, equivalents and marketable securities $27.9M at Mar 31, down from $35.0M at Dec 31, 2023; expected to fund operations into Q4 2024.
Net loss $11.1M ($0.09/shr) vs $11.8M ($0.15/shr) YoY; R&D expenses fell to $5.9M from $7.4M.
Long-term VISIONARY-MS extension: significant vision improvement (up to 38 letters, p<0.001) and cognition (SDMT +29 points, p<0.001).
Received $7.3M NIH sub-award for ALS Expanded Access Program; company advancing FDA discussions for NDA filing in H2 2024.
Peer-reviewed publication in ACS journal characterized CNM-Au8 protein corona supporting neuroprotective mechanism.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Clene Inc. reported first quarter 2024 results: net income net loss of $11.1 million, EPS $0.09 per share.

Period: first quarter 2024
Net income: net loss of $11.1 million
EPS: $0.09 per share
Result: reported results

Exact text from the filing

Clene reported a net loss of $11.1 million , or $0.09 per share, for the quarter ended March 31, 2024

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Clene Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-015212

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.